Monday, 16 September 2013

Sun Pharmaceutical gains as its arm receives USFDA approval for generic Prevacid

Sun Pharmaceutical Industries’ subsidiary has been granted the US Food and Drug Administration (USFDA) final approval for its Abbreviated New Drug Applications (ANDA) for generic version of Prevacid, Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg.

Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg are therapeutic equivalents of Takeda’s Prevacid Delayed-Released Capsules. These Capsules have annual sales of approximately $430 million in the US. Lansoprazole Delayed-Release Capsules USP is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer. Prevacid is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

No comments:

Post a Comment